AnalystBook Research · Company Intelligence

Leonardo DRS, Inc.

DRSNasdaq

Built from Leonardo DRS, Inc.'s own SEC filings · updates as new filings land · sources cited throughout

or browse all covered companies

Revenue increased 12.8% to $3.65B, while Net income increased 30.5% to $278.0M.

The read at a glance✓ Audited against SEC data
  • ScaleFY2025 revenue $3.65BOK
  • ProfitabilityNet income $278.0MOK
  • Cash generationFree cash flow $227.0MOK
  • AccountingFormula-grey distress score · no manipulation flag · earnings quality safeNote
  • Insiders0 buys; 18 sells in 365 daysNote
  • Capitalshare repurchases were $35.0MNote

Business

Leonardo DRS, Inc.: our business not to develop as we expect, and it is not possible for us to predict all of them.

Where the revenue comes from

Fiscal 2025, as Leonardo DRS, Inc. reports it. History and quarterly detail are in the app.

  • ASC$2.4B
  • IMS$1.3B

Leadership changes

From Leonardo DRS, Inc.'s own filings, the day they're filed.

  • Reuben Jeffery III · director · departureeff. 2026-04-01
  • David W. Carey · Directors · departureeff. 2026-03-06
  • Sally A. Wallace · Chief Operating Officer · appointmenteff. 2026-01-01

Latest filings

  • 10-Q · Quarterly report2026-07-30
  • 8-K · Company announcement2026-07-30
  • 8-K · Company announcement2026-07-28
  • 8-K · Company announcement2026-07-17
  • 8-K · Company announcement2026-05-14
In the full recordFree for 14 days
  • What changed🔒
  • Insider signal🔒
  • Growth quality🔒
  • Margins & accounting🔒
  • Capital allocation🔒
  • Real risks🔒
  • The long arc🔒
  • Company history🔒
  • The filings, readable — with what changed vs the prior year highlighted🔒
  • Full financial statements, industry-aware, sources cited throughout🔒
  • Forensic score history & components — the trend, not one year🔒
  • Ownership: insider buys/sells, clusters, activist stakes🔒
  • Ana — ask about Leonardo DRS, Inc., every answer cited to the official filings🔒

Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.

14-day free trial, no credit card. For research purposes only; not investment advice.